A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well
as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA
damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed
to cause DNA damage of skin cells, as well as the extent of skin repair before and after
treatment.